Latest Content

Practical examples of advanced practice provider–led initiatives that improve safety, symptom management, and patient outcomes.

The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk severe or fatal toxicities.

Investigator Elizabeth Lee, MD, discusses efficacy and safety data for rinatabart sesutecan in patients with endometrial cancer.

A look at the current state of cancer, from survival rates to federal research budgets.

Kelly Grosklags, LICSW, BCD, FAAGC, FT, shares advice for dealing with grief in oncology nursing, from treating patients in denial to showing emotion in front of them.

Dato-DXd has been given priority review for the treatment of patients with unresectable/metastatic triple-negative breast cancer.

Multicancer early detection tests may expand screening options, but does the benefit outweigh the uncertainties?

In a world of unfamiliarity and uncertainty, patient advocates help guide those with cancer through challenging diagnoses and the decisions that come with them.

Nurses are called to honor Alex Pretti’s memory through compassion and action.

Updates in ovarian cancer include multiple fast track designations and breakthrough therapy status for new drugs in the clinical space.

The FDA approved subcutaneous daratumumab/VRd in patients with newly diagnosed multiple myeloma who are not eligible for ASCT. Here’s what you should know.

Plus, a phase 1 breast cancer vaccine, updated NCCN guidelines, and a combination with standard-of-care potential in triple-negative breast cancer.

The frontline combination of nivolumab and ipilimumab demonstrated long-term safety and efficacy in patients with unresectable hepatocellular carcinoma.